Business
SOPHiA GENETICS Joins CancerX to Help Accelerate Cancer Research
As a leader in data-driven medicine, SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot BOSTON and LAUSANNE, Switzerland, June 2, 2023
About this update from Sophia Genetics Sa
[{"type":"text","content":"As a leader in data-driven medicine, SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot\nBOSTON and LAUSANNE, Switzerland, June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX, a new public-private partnership formed to rapidly accelerate the pace of cancer innovation in the United States. As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research. SOPHiA GENETICS offers its SOPHiA DDM™ Platform, powered by artificial intelligence and machine learning, to help advance the inaugural project, which looks to improve equity and reduce cost in cancer treatments. \n\n \n \n \n \n \n \n\n \nCancerX was announced by the White House in February 2023 as part of the reignited national Cancer Moonshot initiative. Co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), CancerX will unite stakeholders and innovators to unleash the power of innovation and create a future that is free of the burden of cancer.\n\"As a leader in data-driven medicine, SOPHiA GENETICS is eager to join forces with CancerX and its partners that will lend their expertise towards expediting cancer research and innovation in the U.S.,\" said Kevin Puylaert, Vice President, Business Development & Marketing for SOPHiA GENETICS. \"CancerX founding member Memorial Sloan Kettering Cancer Center (MSK) is among the 750+ institutions within our global data-sharing network. We look forward to leveraging the collective intelligence that our platform creates to help progress cancer research as we embark on our work with CancerX.\"\nIn early 2022, President Biden reignited the Cancer Moonshot, setting new national goals to cut the death rate from cancer by at least 50 percent over the next 25 years and improve the experience of people and their families living with and surviving cancer. In February 2023, the White House announced CancerX, which strives to unite a diverse and i...